4//SEC Filing
ARIAD PHARMACEUTICALS INC 4
Accession 0001395064-21-000203
CIK 0001745020operating
Filed
Oct 14, 8:00 PM ET
Accepted
Oct 15, 6:40 PM ET
Size
9.9 KB
Accession
0001395064-21-000203
Insider Transaction Report
Form 4
TAKEDA PHARMACEUTICAL CO LTD
10% Owner
Transactions
- Conversion
Series A Preferred Stock
2021-10-12−1,615,427→ 0 total(indirect: See explanation)→ Common Stock (1,615,427 underlying) - Conversion
Common Stock
2021-10-12+1,615,427→ 1,615,427 total(indirect: See explanation)
ARIAD PHARMACEUTICALS INC
10% Owner
Transactions
- Conversion
Common Stock
2021-10-12+1,615,427→ 1,615,427 total(indirect: See explanation) - Conversion
Series A Preferred Stock
2021-10-12−1,615,427→ 0 total(indirect: See explanation)→ Common Stock (1,615,427 underlying)
Footnotes (3)
- [F1]Each share of Series A Preferred Stock converted into shares of the Issuers Common Stock at the close of the Issuers initial public offering without payment of additional consideration. The Series A Preferred Stock had no expiration date.
- [F2]This statement is being filed jointly by Takeda Pharmaceutical Company Limited and ARIAD Pharmaceuticals, Inc.
- [F3]The reportable securities are owned directly by ARIAD Pharmaceuticals, Inc. Takeda Pharmaceutical Company Limited's beneficial ownership of these securities is comprised of the reportable securities owned by ARIAD Pharmaceuticals, Inc. ARIAD Pharmaceuticals, Inc., is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%). Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Documents
Issuer
Theseus Pharmaceuticals, Inc.
CIK 0001745020
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000884731
Filing Metadata
- Form type
- 4
- Filed
- Oct 14, 8:00 PM ET
- Accepted
- Oct 15, 6:40 PM ET
- Size
- 9.9 KB